Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma. A feasibility study

Cancer. 1991 Jan 15;67(2):357-62. doi: 10.1002/1097-0142(19910115)67:2<357::aid-cncr2820670207>3.0.co;2-9.

Abstract

Fifty patients with non resectable and/or inoperable bronchogenic carcinoma were entered into a feasibility study of cisplatin (CDDP) given in continuous infusion with concurrent radiation therapy. The radiation therapy regimen consisted of 2 Gy given 5 days a week in the first 3 and last 2 weeks of a 7-week split course (50 Gy of total dose). The CDDP (daily dose of 4 to 6 mg/m2) was administered to cover the days of radiation treatment by means of a central venous catheter and a portable pump. Less than 1% of predicted duration of infusion was lost due to complications related to venous access and pump. Toxicity was moderate. The overall probability of a locoregional major response (complete + partial) within 1 month after treatment completion was 86%. Twenty-three patients underwent resection. The 1-year actuarial probability of survival was 64%. The high response and survival rates warrant further studies on concurrent CDDP continuous infusion and radiation therapy in inoperable lung carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Bronchogenic / mortality
  • Carcinoma, Bronchogenic / pathology
  • Carcinoma, Bronchogenic / secondary
  • Carcinoma, Bronchogenic / therapy*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Feasibility Studies
  • Female
  • Humans
  • Infusions, Intravenous
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Radiotherapy Dosage
  • Survival Rate

Substances

  • Cisplatin